Japan
· Delayed Price · Currency is JPY TMS Co., Ltd. Company Description
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities.
The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia.
It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited.
TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
| Country | Japan |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Takuro Wakabayashi |
Contact Details
Address: 1-9, Fuchu-shi Fuchu, 183-0055 Japan | |
| Phone | 81 42 307 7480 |
| Website | tms-japan.co.jp |
Stock Details
| Ticker Symbol | 4891 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | March - February |
| Reporting Currency | JPY |
| ISIN Number | JP3544960002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Takuro Wakabayashi | Chief Executive Officer |
| Tsuyoshi Ito | Chief Financial Officer |